The ACCESS trial shows mismatched unrelated donors can provide excellent outcomes, addressing racial disparities in donor ...

Panelists discuss how real-world practice often diverges from guideline recommendations due to access barriers, toxicity ...

Panelists discuss how the next generation of targeted agents, including sunvozertinib, BLU-945, and antibody-drug conjugates, ...

Quality of life emerges as a central theme, with panelists emphasizing that patient-reported outcomes and psychosocial ...

T-DXd plus pertuzumab improved quality-of-life outcomes, with fewer skin and mucosal symptoms but more gastrointestinal issues compared to the standard regimen. Both treatment arms showed similar pain ...

Aromatase inhibitors demonstrated superior disease-free survival and time to distant recurrence compared to SERMs in HR+/HER2+ early breast cancer. The benefits of aromatase inhibitors were consistent ...

The TKI plus InO-based therapy for newly diagnosed Ph+ ALL successfully met the efficacy end point, achieving an 81% MR3+ rate within 2 courses with limited cycles of InO. The modified schema 2 ...

The combination of talquetamab-tgvs and pomalidomide achieved an 85.7% objective response rate in relapsed/refractory multiple myeloma patients. Median progression-free survival was 25.8 months, with ...

Giredestrant significantly improved IDFS in ER-positive, HER2-negative early breast cancer, reducing recurrence or death risk by 30% compared to SOC endocrine therapy. Subgroup analyses showed ...

During a live event, Yelena Y. Janjigian, MD, moderated a discussion on how to use PD-L1 CPS status when considering ...

James Essell, MD, Sarah Cannon Research Institute at OHC, the US Oncology Network, discusses the benefits of a remote ...

During a live event, Moshe C. Ornstein, MD, MA, discussed the recommended regimens for non–clear cell renal cell carcinoma ...